Aviragen Therapeutics Inc (NASDAQ:AVIR) shot up 7.5% on Tuesday . The company traded as high as $0.62 and last traded at $0.57. 1,388,500 shares were traded during trading, an increase of 281% from the average session volume of 364,497 shares. The stock had previously closed at $0.53.
Separately, HC Wainwright restated a “hold” rating on shares of Aviragen Therapeutics in a research report on Monday, November 6th.
The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.63 and a current ratio of 6.63.
An institutional investor recently bought a new position in Aviragen Therapeutics stock. Virtu KCG Holdings LLC bought a new position in shares of Aviragen Therapeutics Inc (NASDAQ:AVIR) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 222,934 shares of the biotechnology company’s stock, valued at approximately $149,000. Virtu KCG Holdings LLC owned about 0.58% of Aviragen Therapeutics as of its most recent SEC filing. Institutional investors own 24.20% of the company’s stock.
Aviragen Therapeutics Company Profile
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.
Receive News & Ratings for Aviragen Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviragen Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.